A study of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line treatment in patients with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Cancer
Head and Neck Cancer
Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Results
Download

Study results

LPS BO42533 SKYSCRAPER-09 Final Results May 2026 English (PDF, 0.3 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line treatment in patients with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck

Study results

LPS BO42533 SKYSCRAPER-09 Final Results May 2026 English (PDF, 0.3 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A study of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line treatment in patients with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck

For the latest version of this information please go to www.forpatients.roche.com